Request for Information; Potential Changes to the Policies for Oversight of Dual Use Research of Concern (DURC) and the Potential Pandemic Pathogen Care and Oversight (P3CO) Policy Framework, 60513-60516 [2023-18906]
Download as PDF
60513
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
that allows users to view the Contact
Officials currently on file for the
employer. Users will be able to edit and
delete existing Contact Officials, as well
as add new Contact Officials. The screen
to edit and add Contact Officials collects
essentially the same information as the
approved paper Form G–117a. The
internet version provides for the
required notices and certifications,
contains help messages to ensure users
provide valid contact information, and
prevents users from deleting Contact
Officials without first providing a
replacement.
Completion is voluntary. One
response is requested from each
respondent.
Previous Requests for Comments: The
RRB has already published the initial
60-day notice (88 FR 41994 on June 28,
2023) required by 44 U.S.C. 3506(c)(2).
That request elicited no comments.
Information Collection Request (ICR)
Title: Designation of Contact Officials.
OMB Control Number: 3220–0200.
Form(s) submitted: G–117A & G–117A
(internet).
Type of request: Revision of a
currently approved collection.
Affected public: Private sector;
businesses or other for profits.
Abstract: The Railroad Retirement
Board (RRB) requests that railroad
employers designate employees to act as
Annual
responses
Form No.
Time
(minutes)
Burden
(hours)
G–117A ........................................................................................................................................
G–117a (Internet) ........................................................................................................................
25
200
15
5
6
17
Total ......................................................................................................................................
225
........................
23
Additional Information or Comments:
Copies of the forms and supporting
documents can be obtained from
Kennisha Money at (312) 469–2591 or
Kennisha.Money@rrb.gov. Comments
regarding the information collection
should be addressed to Brian Foster,
Railroad Retirement Board, 844 North
Rush Street, Chicago, Illinois 60611–
1275 or Brian.Foster@rrb.gov.
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Brian Foster,
Clearance Officer.
[FR Doc. 2023–18980 Filed 8–31–23; 8:45 am]
BILLING CODE 7905–01–P
OFFICE OF SCIENCE AND
TECHNOLOGY POLICY
lotter on DSK11XQN23PROD with NOTICES1
liaison with the RRB on a variety of
Railroad Retirement Act and Railroad
Unemployment Insurance Act matters.
Changes proposed: The RRB proposes
to change the Form G–117a (Paper) by
adding updated language in section 12,
Signature line. The language proposed
is, ‘‘The above officials of this employer
are authorized to serve in the capacities
indicated and to act as trusted referees
for the RRB in accordance with the
National Institute of Standards and
Technology (NIST) Special Publication
800–63A guidelines for online reporting
access.’’ The RRB proposes no changes
to Form G–117a (internet).
The burden estimate for the ICR is as
follows:
Request for Information; Potential
Changes to the Policies for Oversight
of Dual Use Research of Concern
(DURC) and the Potential Pandemic
Pathogen Care and Oversight (P3CO)
Policy Framework
Office of Science and
Technology Policy (OSTP).
ACTION: Notice of request for
information.
AGENCY:
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
Life sciences research is vital
for improving health outcomes and
protecting the Nation from infectious
disease threats, but a small subset of this
research could potentially pose risk of
accidents or misuse that could harm
human health. It is important to
regularly evaluate and update biosafety
and biosecurity oversight policies to
keep pace with new technological
developments and the evolving risk
landscape. The Office of Science and
Technology Policy (OSTP) invites
comments on potential changes to the
Policies for Federal and Institutional
Oversight of Life Sciences Dual Use
Research of Concern (DURC) and
Recommended Policy Guidance for
Departmental Development of Review
Mechanisms for Potential Pandemic
Pathogen Care and Oversight (P3CO).
These policies establish frameworks for
review and oversight requirements for
certain categories of life sciences
research, namely research with certain
pathogens and toxins, including at
institutions that accept Federal funding
for such research. These requirements
are intended to complement activities
under existing Federal regulations or
guidelines such as the Federal Select
Agent Program. OSTP requests
comments on how potential changes to
these research oversight policies could
mitigate risks associated with DURC and
research with enhanced potential
pandemic pathogens (ePPP) while
minimizing undue burden on
institutions. The public input provided
through this Request for Information
(RFI) will inform policy evaluations and
SUMMARY:
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
issuance of a revised policy (Revised
Policy).
Responses are due by 11:59 p.m.
Eastern Time on October 16, 2023.
Submissions received after the deadline
may not be taken into consideration.
ADDRESSES: Comments must be
submitted via the Federal eRulemaking
Portal at regulations.gov. However, if
you require an accommodation or
cannot otherwise submit your
comments via regulations.gov, please
use the email or phone number listed
under FOR FURTHER INFORMATION
CONTACT. OSTP will not accept
comments by fax or by email. To ensure
that OSTP does not receive duplicate
copies, please submit your comments
only once. Additionally, please include
the Docket ID (EOP–2023–0001) at the
top of your comments.
Federal eRulemaking Portal: Go to
www.regulations.gov to submit your
comments electronically. Information
on how to use Regulations.gov,
including instructions for accessing
agency documents, submitting
comments, and viewing the docket, is
available on the site under ‘‘FAQ’’
(https://www.regulations.gov/faq).
Privacy Note: OSTP’s policy is to
make all comments received from
members of the public available for
public viewing in their entirety on the
Federal eRulemaking Portal at
www.regulations.gov. Therefore,
commenters should be careful to
include in their comments only
information that they wish to make
publicly available. OSTP requests that
DATES:
E:\FR\FM\01SEN1.SGM
01SEN1
60514
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
no proprietary information, copyrighted
information, or personally identifiable
information be submitted in response to
this RFI.
Instructions: Response to this RFI is
voluntary. Each individual or
organization is requested to submit only
one response. Commenters can respond
to one or multiple questions.
Submissions are suggested to not exceed
the equivalent of ten (10) pages in 12
point or larger font. Submissions should
clearly indicate which questions are
being addressed. Responses should
include the name(s) of the person(s) or
organization(s) filing the response.
Responses containing references,
studies, research, and other empirical
data that are not widely published
should include copies of or electronic
links to the referenced materials.
Responses containing profanity,
vulgarity, threats, or other inappropriate
language or content will not be
considered.
Please note that the U.S. Government
will not pay for response preparation, or
for the use of any information contained
in the response. A response to this RFI
will not be viewed as a binding
commitment to develop or pursue the
project or ideas discussed.
FOR FURTHER INFORMATION CONTACT:
Direct questions to Asad Ramzanali,
research-oversight-policy@ostp.eop.gov,
or 202–456–4444.
Life
sciences research is essential to the
scientific advances that underpin
improvements in the health and safety
of the public, agricultural crops, and
other plants, animals, and the
environment. While life sciences
research provides enormous benefits to
society, there can be risks associated
with certain subsets of work, typically
related to biosafety and biosecurity, that
can and should be mitigated. The
United States has existing,
complementary statutes, regulations,
policies, and guidelines that address
these potential biosafety and biosecurity
risks, particularly those associated with
research oversight and management.1
Together these existing regulatory
authorities and guidelines provide a
foundation to ensure that scientific
lotter on DSK11XQN23PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
1 Examples include: Select Agents and Toxins
Regulations (42 CFR part 73, 9 CFR part 121, and
7 CFR part 331); National Institutes of Health
Guidelines on Research Involving Recombinant and
Synthetic Nucleic Acids; (https://osp.od.nih.gov/
wp-content/uploads/NIH_Guidelines.pdf); Biosafety
in Microbiological & Biomedical Laboratories
(BMBL) 6th Edition (https://www.cdc.gov/labs/
BMBL.html); Additional U.S. Laws, Regulations and
Guidelines (https://www.phe.gov/s3/law/Pages/
default.aspx).
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
research and innovation is safe and
secure.
Scientists, institutions, and the USG
have gained valuable insight over the
past decade from implementing research
oversight policies such as the policies
for oversight of DURC 2 and the P3CO
Policy Framework.3 During this time,
advances in science and technology
have occurred that present realized and
potential future benefits. However, these
advances also present potential risks of
misuse. The National Science Advisory
Board for Biosecurity (NSABB), a
Federal advisory committee that
addresses issues related to biosecurity
and dual use research, provided
recommendations in a March 2023
report 4 to inform United States
Government (USG) policy evaluations
and the development of a more
comprehensive and integrated
framework for the oversight of research
with pathogens and toxins that may
pose significant biosafety or biosecurity
risks. Since the release of this report,
OSTP has been working with Federal
departments and agencies to review,
harmonize, and revise these policies in
accordance with USG goals of
promoting safe and secure biological
practices and strengthening responsible
conduct for biological research as
outlined in the 2022 National
Biodefense Strategy and Implementation
Plan.5
The policy review and revision
process has three broad goals:
1. Assess whether and how to merge
the existing Federal DURC, Institutional
DURC, and P3CO policies into a
harmonized policy that addresses
oversight for research with pathogens
and toxins.
2. Consider revising the scope of the
Federal DURC, Institutional DURC, and
P3CO policies to include a broader set
of pathogens and toxins, including—but
not limited to—biological select agents
2 United States Government Policy for Oversight
of Life Sciences Dual Use Research of Concern
(https://www.phe.gov/s3/dualuse/Documents/uspolicy-durc-032812.pdf); United States Government
Policy for Institutional Oversight of Life Sciences
Dual Use Research of Concern (https://
www.phe.gov/s3/dualuse/Documents/durcpolicy.pdf).
3 Recommended Policy Guidance for
Departmental Development of Review Mechanisms
for Potential Pandemic Pathogen Care and
Oversight (P3CO) (https://www.phe.gov/s3/dualuse/
Documents/P3CO-FinalGuidanceStatement.pdf).
4 Proposed Biosecurity Oversight Framework for
the Future of Science (nih.gov); https://
osp.od.nih.gov/wp-content/uploads/2023/03/
NSABB-Final-Report-Proposed-BiosecurityOversight-Framework-for-the-Future-of-Science.pdf.
5 National Biodefense Strategy and
Implementation Plan: https://www.whitehouse.gov/
wp-content/uploads/2022/10/National-BiodefenseStrategy-and-Implementation-Plan-Final.pdf.
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
and toxins (BSAT) that impact humans
or have the potential to impact humans.
3. Examine ways to strengthen
effective implementation of oversight
for life sciences research on pathogens
and toxins throughout the research
lifecycle.
The USG acknowledges that effective
oversight helps maintain public trust in
the life sciences research enterprise by
demonstrating that the scientific
community recognizes the implications
of research conducted and is acting
responsibly to protect public welfare
and preserve national security.
Scope: OSTP invites comment from
any interested stakeholders. In
particular, OSTP is interested in input
from research institutions, including
both domestic and international entities,
currently subject to the PC3O Policy or
the DURC policies or that may be
subject to the revised scope of a
potential policy update, researchers
within those institutions, scientific and
professional organizations, and
organizations representing diverse
interests across the U.S. research
ecosystem.
Information Requested: Respondents
may provide information for one or
more of the topics included below.
Respondents are asked to note the
corresponding number/s to which
responses pertain.
1. The NSABB recommended that
USG develop an integrated approach to
oversight of research that raises
significant biosafety and biosecurity
concerns, including ePPP research and
DURC (Recommendation 1). By merging
the existing Federal DURC, Institutional
DURC, and P3CO policies into a
harmonized policy, a merged policy
could potentially adopt the institutional
applicability outlined in the
Institutional DURC policy framework,
making the following entities subject to
a Revised Policy:
• U.S. Government departments and
agencies that fund, sponsor, or conduct
life sciences research.
• Institutions within the United
States or its territories that both:
D Receive U.S. Government funds to
conduct or sponsor life sciences
research; and,
D Conduct or sponsor research that is
within the revised scope, regardless of
the source of the funding for the specific
project.
• Institutions outside of the United
States that receive U.S. Government
funds to conduct or sponsor research
that falls under the scope.
(a) What are the anticipated benefits
and challenges of applying a Revised
Policy, inclusive of both DURC and
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
ePPP research, to the scope of entities
outlined above?
(b) What are the anticipated benefits
and challenges of investigators and
institutions having primary
responsibility for identification of both
DURC and ePPP research?
(c) What types of resources or tools
would be useful for researchers and
institutions to determine if their
research falls into a revised policy scope
that is risk-based rather than list-based,
and adequately conduct risk
assessments to identify DURC and ePPP
research?
2. Currently, the scope of the DURC
policies is research that uses one or
more of 15 listed agents or toxins and
that produces, or is anticipated to
produce, any of seven listed
experimental effects. The NSABB
recommended that the scope of research
requiring review for potential DURC
should include research that directly
involves any human, animal, or plant
pathogen, toxin, or agent that is
reasonably anticipated to result in one
or more of the seven experimental
effects outlined in the DURC policy 6
(Recommendation 10.1).
a. Considering the diversity of
federally-funded research settings and
portfolios, how would adoption of
NSABB’s Recommendation 10.1 affect
policy implementation and research
programs at the institutional level?
b. Rather than including any pathogen
within the scope of DURC review, one
possible modification of
Recommendation 10.1 would be to
include DURC experiments that utilize:
i. HHS and Overlap Biological Select
Agent and Toxins (BSAT) List 7 and/or
ii. Pathogen risk group (RG)
classification of 3 or 4 8 and/or
iii. Any pathogen where the conduct
of work (e.g., one of the DURC
experimental categories) would require
biosafety level 3 or 4 containment.
Would a modification of
Recommendation 10.1, in line with the
outlined scope of pathogens above, be
useful for policy implementation? What
specific benefits, challenges, and/or
gaps are anticipated by this revised
scope?
6 United States Government Policy for Oversight
of Life Sciences Dual Use Research of Concern
(https://www.phe.gov/s3/dualuse/Documents/uspolicy-durc-032812.pdf); United States Government
Policy for Institutional Oversight of Life Sciences
Dual Use Research of Concern (https://
www.phe.gov/s3/dualuse/Documents/durcpolicy.pdf).
7 Select Agents and Toxins Regulations (42 CFR
part 73, 9 CFR part 121, and 7 CFR part 331).
8 Risk groups as defined in ‘‘NIH Guidelines for
Research Involving Recombinant or Synthetic
Nucleic Acid Molecules’’ (https://osp.od.nih.gov/
wp-content/uploads/2019_NIH_Guidelines.htm).
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
c. Are there other risk-based
approaches that would expand the
scope beyond the current list of 15
agents and toxins provided in the DURC
policy that would facilitate the
identification of research that poses
significant risks by investigators and
institutions while not resulting in
undue burdens?
d. Given the possible revised scope of
research requiring review for potential
DURC, what modifications, if any, to the
current DURC policy list of 7
experimental effects should be
considered for a Revised Policy that
captures appropriate research without
hampering research progress?
e. What resources or tools would be
valuable to assist with implementation
of a DURC policy with a scope that is
revised to include more than the current
list of 15 agents and toxins?
3. A PPP is currently defined in the
P3CO policy framework 9 as: ‘‘a
pathogen that satisfies both of the
following: 1. It is likely highly
transmissible and likely capable of wide
and uncontrollable spread in human
populations; and 2. It is likely highly
virulent and likely to cause significant
morbidity and/or mortality in humans.’’
The NSABB recommended that the
definition of PPP be modified to: (1)
Likely moderately or highly
transmissible and likely capable of wide
and uncontrollable spread in human
populations; and/or (2) Likely
moderately or highly virulent and likely
to cause significant morbidity and/or
mortality in humans; and, in addition
(3) Likely to pose a severe threat to
public health, the capacity of public
health systems to function, or national
security’’ (Recommendation 2).
(a) How would the change in the
definition of PPP affect the overall scope
of a Revised Policy and its subsequent
implementation?
(b) One possible modification to the
NSABB PPP definition is to specify a
respiratory route of transmission within
clause (1). Would that definition of PPP
be an appropriate scope to mitigate risks
and enhance effective implementation?
(c) Do you have additional
suggestions to modify the PPP definition
to mitigate the most significant risks not
currently addressed and enhance
effective implementation, while limiting
negative or unintended consequences
and burden on researchers, institutions,
and the Federal government?
(d) Are there characteristics related to
human pathology, pathogen
9 Recommended Policy Guidance for
Departmental Development of Review Mechanisms
for Potential Pandemic Pathogen Care and
Oversight (P3CO) (https://www.phe.gov/s3/dualuse/
Documents/P3CO-FinalGuidanceStatement.pdf).
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
60515
characteristics, or other features that
would be helpful to clarify the intent of
‘‘moderately virulent’’? Are there
characteristics related to human
pathology that would be helpful to
clarify the intent of ‘‘moderately
transmissible’’?
4. A Government Accountability
Office (GAO) report from January
2023 10 recommended that the
Department of Health and Human
Services funding agencies should
develop and document a standard to
define ‘‘reasonably anticipated’’ to
ensure consistency in identifying
research that falls within scope of a
Revised Policy. One possible definition
of ‘‘reasonably anticipated’’ is:
‘‘ ‘Reasonably anticipated’ describes
an assessment of an outcome that an
individual with scientific expertise
relevant to the research in question
would expect this outcome to occur
with a non-trivial likelihood. It does not
require high confidence that the
outcome will definitely occur and
excludes experiments in which an
expert would anticipate the outcome to
be technically possible, but highly
unlikely.’’
(a) Does this definition of ‘‘reasonably
anticipated’’ provide additional clarity
to ensure greater consistency in
identifying research that falls within
scope of the Revised Policy? What
modifications to this definition (if any)
would be most helpful?
5. NSABB recommends the removal of
blanket exclusions for research activities
associated with surveillance and
vaccine development or production for
research with ePPPs (Recommendation
3).
(a) Should exemptions for certain
activities be included in a Revised
Policy?
(b) What are the benefits and
drawbacks of including exemptions for
domestic and international pandemic
preparedness, biosafety, biosecurity,
and global health security?
(c) If exemptions are included, how
could they be bounded to maximize
safety and security and minimize
negative impact on domestic and global
public health including outbreak and
pandemic preparedness and response?
For example, would vaccine research
and development activities be
unjustifiably impeded if the current
P3CO policy framework exemption for
‘‘Activities associated with developing
and producing vaccines, such as
generation of high growth strains’’ was
either removed completely or modified
10 Public Health Preparedness: HHS Could
Improve Oversight of Research Involving Enhanced
Potential Pandemic Pathogens. (GAO–23–105455).
E:\FR\FM\01SEN1.SGM
01SEN1
60516
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
to ‘‘Research on PPPs directly associated
with testing and/or producing vaccines,
such as generation of high growth
strains’’?
6. NSABB recommends that
continued assessment of the risks and
benefits associated with advances and
applications of bioinformatics,
modeling, and other in silico
experimental approaches and research
involving genes from or encoding
pathogens, toxins, or other agents must
inform future evaluations of the scope of
research oversight policies to help
ensure that associated risks are
appropriately identified and managed.
(Recommendation 10.2). This type of
research is not currently included in the
DURC and ePPP oversight policies.
(a) Is there a subset of such in silico
research that should require risk
assessment and review in a Revised
Policy, and if so, how should this
research be defined so that the Policy
captures the appropriate research
without hampering activities with
limited biosecurity risks?
(b) One possible way to define this
category of in silico research within a
Revised Policy would be to include
experiments that are reasonably
anticipated to:
‘‘(i) Develop in silico models that
directly enable the predictive design of
an enhanced potential pandemic
pathogen or novel pathogen or toxin
covered under a Revised Policy that
could be constructed via genomic
editing or de novo synthesis; and/or
(ii) Develop a dataset(s) connecting
nucleic acid or amino acid sequences
with experimentally-determined
pathogenic functions in a manner
sufficient to enable the development of
in silico models described in (i).’’
If a new category of research, similar
to the examples provided above, were to
require risk assessment and review in a
Revised Policy, what would be the
benefits and challenges with
implementation?
Dated: August 28, 2023.
Stacy Murphy,
Deputy Chief Operations Officer/Security
Officer.
lotter on DSK11XQN23PROD with NOTICES1
[FR Doc. 2023–18906 Filed 8–31–23; 8:45 am]
BILLING CODE 3270–F1–P
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–98233; File No. SR–ISE–
2023–08]
Self-Regulatory Organizations; Nasdaq
ISE, LLC; Notice of Designation of a
Longer Period for Commission Action
on Proceedings To Determine Whether
To Approve or Disapprove a Proposed
Rule Change, as Modified by
Amendment No. 1, To Make Permanent
Certain P.M.-Settled Pilots
August 28, 2023.
On February 23, 2023, Nasdaq ISE
LLC (‘‘ISE’’ or ‘‘Exchange’’) filed with
the Securities and Exchange
Commission (‘‘Commission’’), pursuant
to section 19(b)(1) of the Securities
Exchange Act of 1934 (‘‘Act’’) 1 and Rule
19b–4 thereunder,2 a proposed rule
change to make permanent the pilot
program to permit the listing and
trading of options based on 1⁄5 the value
of the Nasdaq-100 Index and the
Exchange’s nonstandard expirations
pilot program. The proposed rule
change was published for comment in
the Federal Register on March 2, 2023.3
On April 7, 2023, pursuant to section
19(b)(2) of the Act,4 the Commission
designated a longer period within which
to approve the proposed rule change,
disapprove the proposed rule change, or
institute proceedings to determine
whether to disapprove the proposed
rule change.5 On May 11, 2023, the
Exchange filed Amendment No. 1 to the
proposed rule change (‘‘Amendment No.
1’’).6 On May 31, 2023, the Commission
instituted proceedings to determine
whether to approve or disapprove the
proposed rule change and published
Amendment No. 1 for notice and
comment.7
Section 19(b)(2) of the Exchange Act 8
provides that, after initiating
proceedings, the Commission shall issue
an order approving or disapproving the
proposed rule change not later than 180
days after the date of publication of
notice of filing of the proposed rule
change. The Commission may extend
the period for issuing an order
approving or disapproving the proposed
1 15
U.S.C. 78s(b)(1).
CFR 240.19b–4.
3 See Securities Exchange Act Release No. 96979
(February 24, 2023), 88 FR 13182.
4 15 U.S.C. 78s(b)(2).
5 See Securities Exchange Act Release No. 97261,
88 FR 22509 (April 13, 2023).
6 Amendment No. 1 is available at: https://
www.sec.gov/comments/sr-ise-2023-08/
srise202308.htm.
7 See Securities Exchange Act Release No. 97626,
88 FR 37110 (June 6, 2023).
8 15 U.S.C. 78s(b)(2).
2 17
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
rule change, however, by not more than
60 days if the Commission determines
that a longer period is appropriate and
publishes reasons for such
determination. The proposed rule
change was published for notice and
comment in the Federal Register on
March 2, 2023.9 The 180th day after
publication of the proposed rule change
is August 29, 2023. The Commission is
extending the time period for approving
or disapproving the proposed rule
change for an additional 60 days.
The Commission finds it appropriate
to designate a longer period within
which to issue an order approving or
disapproving the proposed rule change
so that it has sufficient time to consider
the proposed rule change and the issues
raised therein. Accordingly, the
Commission, pursuant to section
19(b)(2) of the Exchange Act,10
designates October 28, 2023, as the date
by which the Commission shall either
approve or disapprove the proposed
rule change (File No. SR–ISE–2023–08).
For the Commission, by the Division
of Trading and Markets, pursuant to
delegated authority.11
Sherry R. Haywood,
Assistant Secretary.
[FR Doc. 2023–18898 Filed 8–31–23; 8:45 am]
BILLING CODE 8011–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–98231; File No. SR–
CboeBZX–2023–062]
Self-Regulatory Organizations; Cboe
BZX Exchange, Inc.; Notice of Filing of
a Proposed Rule Change To Amend
the Initial Period After Commencement
of Trading of a Series of ETF Shares
on the Exchange as It Relates to the
Holders of Record and/or Beneficial
Holders, as Provided in Exchange Rule
14.11(l)
August 28, 2023.
Pursuant to section 19(b)(1) of the
Securities Exchange Act of 1934 (the
‘‘Act’’),1 and Rule 19b–4 thereunder,2
notice is hereby given that on August
14, 2023, Cboe BZX Exchange, Inc. (the
‘‘Exchange’’ or ‘‘BZX’’) filed with the
Securities and Exchange Commission
(the ‘‘Commission’’) the proposed rule
change as described in Items I, II, and
III below, which Items have been
prepared by the Exchange. The
Commission is publishing this notice to
9 See
supra note 3 and accompanying text.
U.S.C. 78s(b)(2).
11 17 CFR 200.30–3(a)(57).
1 15 U.S.C. 78s(b)(1).
2 17 CFR 240.19b–4.
10 15
E:\FR\FM\01SEN1.SGM
01SEN1
Agencies
[Federal Register Volume 88, Number 169 (Friday, September 1, 2023)]
[Notices]
[Pages 60513-60516]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18906]
=======================================================================
-----------------------------------------------------------------------
OFFICE OF SCIENCE AND TECHNOLOGY POLICY
Request for Information; Potential Changes to the Policies for
Oversight of Dual Use Research of Concern (DURC) and the Potential
Pandemic Pathogen Care and Oversight (P3CO) Policy Framework
AGENCY: Office of Science and Technology Policy (OSTP).
ACTION: Notice of request for information.
-----------------------------------------------------------------------
SUMMARY: Life sciences research is vital for improving health outcomes
and protecting the Nation from infectious disease threats, but a small
subset of this research could potentially pose risk of accidents or
misuse that could harm human health. It is important to regularly
evaluate and update biosafety and biosecurity oversight policies to
keep pace with new technological developments and the evolving risk
landscape. The Office of Science and Technology Policy (OSTP) invites
comments on potential changes to the Policies for Federal and
Institutional Oversight of Life Sciences Dual Use Research of Concern
(DURC) and Recommended Policy Guidance for Departmental Development of
Review Mechanisms for Potential Pandemic Pathogen Care and Oversight
(P3CO). These policies establish frameworks for review and oversight
requirements for certain categories of life sciences research, namely
research with certain pathogens and toxins, including at institutions
that accept Federal funding for such research. These requirements are
intended to complement activities under existing Federal regulations or
guidelines such as the Federal Select Agent Program. OSTP requests
comments on how potential changes to these research oversight policies
could mitigate risks associated with DURC and research with enhanced
potential pandemic pathogens (ePPP) while minimizing undue burden on
institutions. The public input provided through this Request for
Information (RFI) will inform policy evaluations and issuance of a
revised policy (Revised Policy).
DATES: Responses are due by 11:59 p.m. Eastern Time on October 16,
2023. Submissions received after the deadline may not be taken into
consideration.
ADDRESSES: Comments must be submitted via the Federal eRulemaking
Portal at regulations.gov. However, if you require an accommodation or
cannot otherwise submit your comments via regulations.gov, please use
the email or phone number listed under FOR FURTHER INFORMATION CONTACT.
OSTP will not accept comments by fax or by email. To ensure that OSTP
does not receive duplicate copies, please submit your comments only
once. Additionally, please include the Docket ID (EOP-2023-0001) at the
top of your comments.
Federal eRulemaking Portal: Go to www.regulations.gov to submit
your comments electronically. Information on how to use
Regulations.gov, including instructions for accessing agency documents,
submitting comments, and viewing the docket, is available on the site
under ``FAQ'' (https://www.regulations.gov/faq).
Privacy Note: OSTP's policy is to make all comments received from
members of the public available for public viewing in their entirety on
the Federal eRulemaking Portal at www.regulations.gov. Therefore,
commenters should be careful to include in their comments only
information that they wish to make publicly available. OSTP requests
that
[[Page 60514]]
no proprietary information, copyrighted information, or personally
identifiable information be submitted in response to this RFI.
Instructions: Response to this RFI is voluntary. Each individual or
organization is requested to submit only one response. Commenters can
respond to one or multiple questions. Submissions are suggested to not
exceed the equivalent of ten (10) pages in 12 point or larger font.
Submissions should clearly indicate which questions are being
addressed. Responses should include the name(s) of the person(s) or
organization(s) filing the response. Responses containing references,
studies, research, and other empirical data that are not widely
published should include copies of or electronic links to the
referenced materials. Responses containing profanity, vulgarity,
threats, or other inappropriate language or content will not be
considered.
Please note that the U.S. Government will not pay for response
preparation, or for the use of any information contained in the
response. A response to this RFI will not be viewed as a binding
commitment to develop or pursue the project or ideas discussed.
FOR FURTHER INFORMATION CONTACT: Direct questions to Asad Ramzanali,
[email protected], or 202-456-4444.
SUPPLEMENTARY INFORMATION: Life sciences research is essential to the
scientific advances that underpin improvements in the health and safety
of the public, agricultural crops, and other plants, animals, and the
environment. While life sciences research provides enormous benefits to
society, there can be risks associated with certain subsets of work,
typically related to biosafety and biosecurity, that can and should be
mitigated. The United States has existing, complementary statutes,
regulations, policies, and guidelines that address these potential
biosafety and biosecurity risks, particularly those associated with
research oversight and management.\1\ Together these existing
regulatory authorities and guidelines provide a foundation to ensure
that scientific research and innovation is safe and secure.
---------------------------------------------------------------------------
\1\ Examples include: Select Agents and Toxins Regulations (42
CFR part 73, 9 CFR part 121, and 7 CFR part 331); National
Institutes of Health Guidelines on Research Involving Recombinant
and Synthetic Nucleic Acids; (https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf); Biosafety in Microbiological &
Biomedical Laboratories (BMBL) 6th Edition (https://www.cdc.gov/labs/BMBL.html); Additional U.S. Laws, Regulations and Guidelines
(https://www.phe.gov/s3/law/Pages/default.aspx).
---------------------------------------------------------------------------
Scientists, institutions, and the USG have gained valuable insight
over the past decade from implementing research oversight policies such
as the policies for oversight of DURC \2\ and the P3CO Policy
Framework.\3\ During this time, advances in science and technology have
occurred that present realized and potential future benefits. However,
these advances also present potential risks of misuse. The National
Science Advisory Board for Biosecurity (NSABB), a Federal advisory
committee that addresses issues related to biosecurity and dual use
research, provided recommendations in a March 2023 report \4\ to inform
United States Government (USG) policy evaluations and the development
of a more comprehensive and integrated framework for the oversight of
research with pathogens and toxins that may pose significant biosafety
or biosecurity risks. Since the release of this report, OSTP has been
working with Federal departments and agencies to review, harmonize, and
revise these policies in accordance with USG goals of promoting safe
and secure biological practices and strengthening responsible conduct
for biological research as outlined in the 2022 National Biodefense
Strategy and Implementation Plan.\5\
---------------------------------------------------------------------------
\2\ United States Government Policy for Oversight of Life
Sciences Dual Use Research of Concern (https://www.phe.gov/s3/dualuse/Documents/us-policy-durc-032812.pdf); United States
Government Policy for Institutional Oversight of Life Sciences Dual
Use Research of Concern (https://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf).
\3\ Recommended Policy Guidance for Departmental Development of
Review Mechanisms for Potential Pandemic Pathogen Care and Oversight
(P3CO) (https://www.phe.gov/s3/dualuse/Documents/P3CO-FinalGuidanceStatement.pdf).
\4\ Proposed Biosecurity Oversight Framework for the Future of
Science (nih.gov); https://osp.od.nih.gov/wp-content/uploads/2023/03/NSABB-Final-Report-Proposed-Biosecurity-Oversight-Framework-for-the-Future-of-Science.pdf.
\5\ National Biodefense Strategy and Implementation Plan:
https://www.whitehouse.gov/wp-content/uploads/2022/10/National-Biodefense-Strategy-and-Implementation-Plan-Final.pdf.
---------------------------------------------------------------------------
The policy review and revision process has three broad goals:
1. Assess whether and how to merge the existing Federal DURC,
Institutional DURC, and P3CO policies into a harmonized policy that
addresses oversight for research with pathogens and toxins.
2. Consider revising the scope of the Federal DURC, Institutional
DURC, and P3CO policies to include a broader set of pathogens and
toxins, including--but not limited to--biological select agents and
toxins (BSAT) that impact humans or have the potential to impact
humans.
3. Examine ways to strengthen effective implementation of oversight
for life sciences research on pathogens and toxins throughout the
research lifecycle.
The USG acknowledges that effective oversight helps maintain public
trust in the life sciences research enterprise by demonstrating that
the scientific community recognizes the implications of research
conducted and is acting responsibly to protect public welfare and
preserve national security.
Scope: OSTP invites comment from any interested stakeholders. In
particular, OSTP is interested in input from research institutions,
including both domestic and international entities, currently subject
to the PC3O Policy or the DURC policies or that may be subject to the
revised scope of a potential policy update, researchers within those
institutions, scientific and professional organizations, and
organizations representing diverse interests across the U.S. research
ecosystem.
Information Requested: Respondents may provide information for one
or more of the topics included below. Respondents are asked to note the
corresponding number/s to which responses pertain.
1. The NSABB recommended that USG develop an integrated approach to
oversight of research that raises significant biosafety and biosecurity
concerns, including ePPP research and DURC (Recommendation 1). By
merging the existing Federal DURC, Institutional DURC, and P3CO
policies into a harmonized policy, a merged policy could potentially
adopt the institutional applicability outlined in the Institutional
DURC policy framework, making the following entities subject to a
Revised Policy:
U.S. Government departments and agencies that fund,
sponsor, or conduct life sciences research.
Institutions within the United States or its territories
that both:
[ssquf] Receive U.S. Government funds to conduct or sponsor life
sciences research; and,
[ssquf] Conduct or sponsor research that is within the revised
scope, regardless of the source of the funding for the specific
project.
Institutions outside of the United States that receive
U.S. Government funds to conduct or sponsor research that falls under
the scope.
(a) What are the anticipated benefits and challenges of applying a
Revised Policy, inclusive of both DURC and
[[Page 60515]]
ePPP research, to the scope of entities outlined above?
(b) What are the anticipated benefits and challenges of
investigators and institutions having primary responsibility for
identification of both DURC and ePPP research?
(c) What types of resources or tools would be useful for
researchers and institutions to determine if their research falls into
a revised policy scope that is risk-based rather than list-based, and
adequately conduct risk assessments to identify DURC and ePPP research?
2. Currently, the scope of the DURC policies is research that uses
one or more of 15 listed agents or toxins and that produces, or is
anticipated to produce, any of seven listed experimental effects. The
NSABB recommended that the scope of research requiring review for
potential DURC should include research that directly involves any
human, animal, or plant pathogen, toxin, or agent that is reasonably
anticipated to result in one or more of the seven experimental effects
outlined in the DURC policy \6\ (Recommendation 10.1).
---------------------------------------------------------------------------
\6\ United States Government Policy for Oversight of Life
Sciences Dual Use Research of Concern (https://www.phe.gov/s3/dualuse/Documents/us-policy-durc-032812.pdf); United States
Government Policy for Institutional Oversight of Life Sciences Dual
Use Research of Concern (https://www.phe.gov/s3/dualuse/Documents/durc-policy.pdf).
---------------------------------------------------------------------------
a. Considering the diversity of federally-funded research settings
and portfolios, how would adoption of NSABB's Recommendation 10.1
affect policy implementation and research programs at the institutional
level?
b. Rather than including any pathogen within the scope of DURC
review, one possible modification of Recommendation 10.1 would be to
include DURC experiments that utilize:
i. HHS and Overlap Biological Select Agent and Toxins (BSAT) List
\7\ and/or
---------------------------------------------------------------------------
\7\ Select Agents and Toxins Regulations (42 CFR part 73, 9 CFR
part 121, and 7 CFR part 331).
---------------------------------------------------------------------------
ii. Pathogen risk group (RG) classification of 3 or 4 \8\ and/or
---------------------------------------------------------------------------
\8\ Risk groups as defined in ``NIH Guidelines for Research
Involving Recombinant or Synthetic Nucleic Acid Molecules'' (https://osp.od.nih.gov/wp-content/uploads/2019_NIH_Guidelines.htm).
---------------------------------------------------------------------------
iii. Any pathogen where the conduct of work (e.g., one of the DURC
experimental categories) would require biosafety level 3 or 4
containment.
Would a modification of Recommendation 10.1, in line with the
outlined scope of pathogens above, be useful for policy implementation?
What specific benefits, challenges, and/or gaps are anticipated by this
revised scope?
c. Are there other risk-based approaches that would expand the
scope beyond the current list of 15 agents and toxins provided in the
DURC policy that would facilitate the identification of research that
poses significant risks by investigators and institutions while not
resulting in undue burdens?
d. Given the possible revised scope of research requiring review
for potential DURC, what modifications, if any, to the current DURC
policy list of 7 experimental effects should be considered for a
Revised Policy that captures appropriate research without hampering
research progress?
e. What resources or tools would be valuable to assist with
implementation of a DURC policy with a scope that is revised to include
more than the current list of 15 agents and toxins?
3. A PPP is currently defined in the P3CO policy framework \9\ as:
``a pathogen that satisfies both of the following: 1. It is likely
highly transmissible and likely capable of wide and uncontrollable
spread in human populations; and 2. It is likely highly virulent and
likely to cause significant morbidity and/or mortality in humans.''
---------------------------------------------------------------------------
\9\ Recommended Policy Guidance for Departmental Development of
Review Mechanisms for Potential Pandemic Pathogen Care and Oversight
(P3CO) (https://www.phe.gov/s3/dualuse/Documents/P3CO-FinalGuidanceStatement.pdf).
---------------------------------------------------------------------------
The NSABB recommended that the definition of PPP be modified to:
(1) Likely moderately or highly transmissible and likely capable of
wide and uncontrollable spread in human populations; and/or (2) Likely
moderately or highly virulent and likely to cause significant morbidity
and/or mortality in humans; and, in addition (3) Likely to pose a
severe threat to public health, the capacity of public health systems
to function, or national security'' (Recommendation 2).
(a) How would the change in the definition of PPP affect the
overall scope of a Revised Policy and its subsequent implementation?
(b) One possible modification to the NSABB PPP definition is to
specify a respiratory route of transmission within clause (1). Would
that definition of PPP be an appropriate scope to mitigate risks and
enhance effective implementation?
(c) Do you have additional suggestions to modify the PPP definition
to mitigate the most significant risks not currently addressed and
enhance effective implementation, while limiting negative or unintended
consequences and burden on researchers, institutions, and the Federal
government?
(d) Are there characteristics related to human pathology, pathogen
characteristics, or other features that would be helpful to clarify the
intent of ``moderately virulent''? Are there characteristics related to
human pathology that would be helpful to clarify the intent of
``moderately transmissible''?
4. A Government Accountability Office (GAO) report from January
2023 \10\ recommended that the Department of Health and Human Services
funding agencies should develop and document a standard to define
``reasonably anticipated'' to ensure consistency in identifying
research that falls within scope of a Revised Policy. One possible
definition of ``reasonably anticipated'' is:
---------------------------------------------------------------------------
\10\ Public Health Preparedness: HHS Could Improve Oversight of
Research Involving Enhanced Potential Pandemic Pathogens. (GAO-23-
105455).
---------------------------------------------------------------------------
`` `Reasonably anticipated' describes an assessment of an outcome
that an individual with scientific expertise relevant to the research
in question would expect this outcome to occur with a non-trivial
likelihood. It does not require high confidence that the outcome will
definitely occur and excludes experiments in which an expert would
anticipate the outcome to be technically possible, but highly
unlikely.''
(a) Does this definition of ``reasonably anticipated'' provide
additional clarity to ensure greater consistency in identifying
research that falls within scope of the Revised Policy? What
modifications to this definition (if any) would be most helpful?
5. NSABB recommends the removal of blanket exclusions for research
activities associated with surveillance and vaccine development or
production for research with ePPPs (Recommendation 3).
(a) Should exemptions for certain activities be included in a
Revised Policy?
(b) What are the benefits and drawbacks of including exemptions for
domestic and international pandemic preparedness, biosafety,
biosecurity, and global health security?
(c) If exemptions are included, how could they be bounded to
maximize safety and security and minimize negative impact on domestic
and global public health including outbreak and pandemic preparedness
and response? For example, would vaccine research and development
activities be unjustifiably impeded if the current P3CO policy
framework exemption for ``Activities associated with developing and
producing vaccines, such as generation of high growth strains'' was
either removed completely or modified
[[Page 60516]]
to ``Research on PPPs directly associated with testing and/or producing
vaccines, such as generation of high growth strains''?
6. NSABB recommends that continued assessment of the risks and
benefits associated with advances and applications of bioinformatics,
modeling, and other in silico experimental approaches and research
involving genes from or encoding pathogens, toxins, or other agents
must inform future evaluations of the scope of research oversight
policies to help ensure that associated risks are appropriately
identified and managed. (Recommendation 10.2). This type of research is
not currently included in the DURC and ePPP oversight policies.
(a) Is there a subset of such in silico research that should
require risk assessment and review in a Revised Policy, and if so, how
should this research be defined so that the Policy captures the
appropriate research without hampering activities with limited
biosecurity risks?
(b) One possible way to define this category of in silico research
within a Revised Policy would be to include experiments that are
reasonably anticipated to:
``(i) Develop in silico models that directly enable the predictive
design of an enhanced potential pandemic pathogen or novel pathogen or
toxin covered under a Revised Policy that could be constructed via
genomic editing or de novo synthesis; and/or
(ii) Develop a dataset(s) connecting nucleic acid or amino acid
sequences with experimentally-determined pathogenic functions in a
manner sufficient to enable the development of in silico models
described in (i).''
If a new category of research, similar to the examples provided
above, were to require risk assessment and review in a Revised Policy,
what would be the benefits and challenges with implementation?
Dated: August 28, 2023.
Stacy Murphy,
Deputy Chief Operations Officer/Security Officer.
[FR Doc. 2023-18906 Filed 8-31-23; 8:45 am]
BILLING CODE 3270-F1-P